BeOne Medicines Ltd. – Sponsored ADR $ONC Shares Bought by Voya Investment Management LLC

Voya Investment Management LLC raised its holdings in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 49.2% during the 3rd quarter, Holdings Channel.com reports. The firm owned 15,490 shares of the company’s stock after acquiring an additional 5,105 shares during the period. Voya Investment Management LLC’s holdings in BeOne Medicines were worth $5,277,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Primecap Management Co. CA acquired a new position in shares of BeOne Medicines in the 2nd quarter valued at about $1,231,720,000. Temasek Holdings Private Ltd acquired a new stake in BeOne Medicines during the second quarter worth about $244,603,000. Marshall Wace LLP purchased a new position in BeOne Medicines during the second quarter valued at approximately $113,190,000. Baird Financial Group Inc. acquired a new position in BeOne Medicines in the second quarter valued at approximately $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in BeOne Medicines in the 2nd quarter worth approximately $73,347,000. 48.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at BeOne Medicines

In other BeOne Medicines news, SVP Chan Henry Lee sold 332 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $325.00, for a total transaction of $107,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 2,627 shares of the stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $340.90, for a total value of $895,544.30. The disclosure for this sale is available in the SEC filing. Insiders sold 138,617 shares of company stock worth $44,632,898 over the last three months. Company insiders own 6.62% of the company’s stock.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $311.73 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.17 and a current ratio of 2.39. The firm has a fifty day moving average of $327.41 and a 200 day moving average of $308.97. The firm has a market cap of $36.95 billion, a PE ratio of 611.24 and a beta of 0.45. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $172.67 and a one year high of $385.22.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Citigroup raised their price objective on shares of BeOne Medicines from $399.00 to $405.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. JPMorgan Chase & Co. raised their price target on shares of BeOne Medicines from $345.00 to $385.00 and gave the company an “overweight” rating in a research report on Wednesday, October 8th. Citizens Jmp lifted their price objective on shares of BeOne Medicines from $348.00 to $396.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Jefferies Financial Group reissued a “buy” rating and set a $420.00 target price on shares of BeOne Medicines in a research note on Monday, November 17th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of BeOne Medicines in a research report on Wednesday, December 17th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $365.79.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.